

SARC Biannual Meeting AgendaJune 4, 2010
8:00 am - 12:00 pm

8:00-8:20	Welcome	
	SARC Update	Larry Baker
	Career Development Award Presentation	Larry Baker
	New Developmental Therapeutics Chair	Chand Khanna
8:20-9:30	Chawla/Rosenfeld Developmental Therapeutics Symposium	
	Preclinical Investigation of TH-302	Charles Hart
	Clinical Experience of TH-302 in Sarcoma	Kristen Ganjoo
	Open Discussion	Chand Khanna
9:30-9:45	Break	
9:45-10:45	SARC Clinical Trials	
	Introduction	Rashmi Chugh
	SARC020 EORTC 62091: Phase IIb/III multicenter study comparing the efficacy of trabectedin administered as a 3-hour or 24-hour infusion to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma	James Butrynski
	SARC019 A Randomized, phase 3 study of dose escalation versus no dose escalation of imatinib in metastatic GIST patients with imatinib trough levels less than 1100 nanograms/mL	James Butrynski
	SARC012 A randomized, double-blinded, placebo-controlled, multi-institutional, phase 2 study of AZD0530, a selective src kinase inhibitor, in patients with recurrent osteosarcoma localized to the lung	Su Young Kim
	SARC006/016 Phase II trial of chemotherapy in sporadic and Neurofibromatosis Type 1 associated high grade malignant peripheral nerve sheath tumors Phase 2 study of the mTOR inhibitor RAD001 (everolimus) in combination with bevacizumab (avastin) in patients with sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors	Brigitte Widemann
10:45-11:15	Imaging Update	
	SARC011- Imaging Review	Larry Schwartz
11:30-12	SARC Investigators Only Meeting	